AU2021411506A1 - Extended release upadacitinib formulations - Google Patents

Extended release upadacitinib formulations Download PDF

Info

Publication number
AU2021411506A1
AU2021411506A1 AU2021411506A AU2021411506A AU2021411506A1 AU 2021411506 A1 AU2021411506 A1 AU 2021411506A1 AU 2021411506 A AU2021411506 A AU 2021411506A AU 2021411506 A AU2021411506 A AU 2021411506A AU 2021411506 A1 AU2021411506 A1 AU 2021411506A1
Authority
AU
Australia
Prior art keywords
dosage form
solid dosage
upadacitinib
extended release
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021411506A
Other languages
English (en)
Other versions
AU2021411506A9 (en
Inventor
Ye Huang
Yihong Qiu
Deliang Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of AU2021411506A1 publication Critical patent/AU2021411506A1/en
Publication of AU2021411506A9 publication Critical patent/AU2021411506A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021411506A 2020-12-29 2021-12-29 Extended release upadacitinib formulations Pending AU2021411506A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063131564P 2020-12-29 2020-12-29
US63/131,564 2020-12-29
PCT/US2021/065443 WO2022147073A1 (en) 2020-12-29 2021-12-29 Extended release upadacitinib formulations

Publications (2)

Publication Number Publication Date
AU2021411506A1 true AU2021411506A1 (en) 2023-07-13
AU2021411506A9 AU2021411506A9 (en) 2024-09-26

Family

ID=82261098

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021411506A Pending AU2021411506A1 (en) 2020-12-29 2021-12-29 Extended release upadacitinib formulations

Country Status (8)

Country Link
US (3) US20240316040A1 (https=)
EP (1) EP4271380A4 (https=)
JP (1) JP2024501051A (https=)
KR (1) KR20230127266A (https=)
AU (1) AU2021411506A1 (https=)
CA (1) CA3206839A1 (https=)
MX (1) MX2023007741A (https=)
WO (1) WO2022147073A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
CA3248817A1 (en) * 2022-01-20 2023-07-27 Renata Pharmaceutical (Ireland) Limited Extended-release pharmaceutical composition of Upadacitinib
EP4583877A1 (en) * 2022-09-09 2025-07-16 Intas Pharmaceuticals Ltd. Upadacitinib formulation
CN117357492A (zh) * 2023-10-31 2024-01-09 苏州天马医药集团天吉生物制药有限公司 一种乌帕替尼缓释片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003453A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Barra de empuje oros para el suministro controlado de agentes activos.
US20090099154A1 (en) * 2005-06-29 2009-04-16 Panacea Biotec Ltd. Pharmaceutical Sustained Release Compositions and Processes Thereof
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US20140271892A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles having good auc
AU2018230500B2 (en) * 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis
AU2018312349A1 (en) * 2017-08-01 2020-02-06 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
WO2020115212A1 (en) * 2018-12-05 2020-06-11 Lek Pharmaceuticals D.D. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib

Also Published As

Publication number Publication date
WO2022147073A1 (en) 2022-07-07
JP2024501051A (ja) 2024-01-10
AU2021411506A9 (en) 2024-09-26
MX2023007741A (es) 2023-09-15
KR20230127266A (ko) 2023-08-31
US20240316040A1 (en) 2024-09-26
US20250161302A1 (en) 2025-05-22
CA3206839A1 (en) 2022-07-07
EP4271380A4 (en) 2025-01-22
US20260007661A1 (en) 2026-01-08
EP4271380A1 (en) 2023-11-08

Similar Documents

Publication Publication Date Title
US20260007661A1 (en) Extended release upadacitinib formulations
JP5634882B2 (ja) 弱塩基性薬物と有機酸とを含む薬物送達システム
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
KR101367814B1 (ko) 위장체류 제제 및 이의 제조 방법
KR20090065524A (ko) 프로그래머블 부력전달기술
JP2016034947A (ja) Ｊａｋ３インヒビターを含む制御型経口投与製剤
CN1938026A (zh) 控释制剂及其制造方法
ES2271514T3 (es) Formulacion de liberacion sostenida para clorhidrato de venlafaxina.
CN105073100A (zh) 坦索罗辛或其盐的药物组合物
ES2963929T3 (es) Forma farmacéutica oral multipartículas que proporciona liberación prolongada de tapentadol
EP2435029B1 (en) Pharmaceutical composition comprising tamsulosin
JP2008524317A (ja) 腸溶コーティングされたアジスロマイシン多粒子
KR101925590B1 (ko) 개선된 생체이용률을 갖는 페노피브릭산 제제
KR20130121717A (ko) 위체류 약물전달 시스템을 이용한 서방성 제제
US20220016058A1 (en) Pharmaceutical composition containing tamsulosin hydrochloride with excellent acid resistance and preparation method therefor
KR101650213B1 (ko) 생체접착성 컴팩트 매트릭스의 제조방법
WO2009087663A2 (en) Oral controlled release coated tablet
EP3764983B1 (en) A sustained release formulation comprising acemetacin with bimodal in vitro release
ES2973959T3 (es) Composición de liberación sostenida que comprende oxalato de tapentadol y método de preparación de la misma
CA2503380A1 (en) Pharmaceutical compositions containing venlafaxine
US20040228918A1 (en) Granule modulating hydrogel system
US20210169807A1 (en) Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
WO2006136927A1 (en) Extended release formulations comprising venlafaxine

Legal Events

Date Code Title Description
SREP Specification republished